Dow Up1.31% Nasdaq Up2.40%

Exelixis, Inc. (EXEL)

1.60 Down 0.05(3.03%) 4:00PM EDT
|After Hours : 1.58 Down 0.02 (1.25%) 6:13PM EDT
ProfileGet Profile for:
Exelixis, Inc.
210 East Grand Avenue
South San Francisco, CA 94080
United States - Map
Phone: 650-837-7000
Fax: 650-837-8300

Index Membership:N/A
Full Time Employees:227

Business Summary 

Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Exelixis, Inc.

Corporate Governance 
Exelixis, Inc.’s ISS Governance QuickScore as of Oct 1, 2014 is 6. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Stelios Papadopoulos Ph.D., 66
Co-Founder, Chairman and Member of Audit Committee
Mr. Michael M. Morrissey Ph.D., 53
Chief Exec. Officer, Pres and Director
Ms. Pamela A. Simonton J.D., LL.M, 64
Exec. VP
Dr. Gisela M. Schwab M.D., 57
Chief Medical Officer and Exec. VP
Mr. J. Scott Garland , 45
Chief Commercial Officer and Exec. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders